Optimizing Clinical Trials with Quantum Machine Learning

Clinical trials are the linchpin of medical advancement, determining whether a new drug is safe and effective for public use. A failed trial doesn’t just represent a financial setback; it delays potentially life-saving treatments from reaching patients who need them most. Understanding and addressing the root causes of trial failures is therefore crucial for both the medical community and society at large.

Optimizing Patient Stratification: Minimizing Discrepancies Between Patient Groups in Clinical Trials

SETTING

Allocating subjects to treatment groups is of great importance in clinical trial design. We must ensure that the different groups of patients are as similar as possible with respect to relevant treatment attributes.

This can be formulated as a constrained optimization problem, minimizing discrepancies between patient groups. Quantum optimization algorithms can offer a powerful alternative to classical optimization software as the number of patients scale.

RESULTS

Our preliminary results indicate that randomization can often produce biases in the covariate distributions, specially when the number of patients increase. Thus, randomizing patients into cohorts can result in significantly higher discrepancies compared to the optimal grouping.

Solving this optimization problem can be challenging for classical solvers, even with a few hundred patients. However, hybrid quantum-classical methods present a powerful alternative, with some of these approaches being over two orders of magnitude faster than classical optimization when handling just 200 patients.

Schedule a Call

Expanding the Impact of QML in Clinical Trials

Biomarker Discovery

Identifying biomarkers to stratify patients into subgroups based on genetic, molecular, or imaging data is a key challenge in personalized medicine. Current approaches tend to focus on single data modality and rely on complex models that lack interpretability.

Quantum optimization enables the creation of a feature selection framework that identifies a set of interpretable, independent features for predicting treatment outcomes and stratifying patients.

Multi-arm Bandit Problem

In clinical trials with multiple treatments, each with unknown effectiveness, the aim is to sequentially assign patients to different arms to quickly determine the best treatment, balancing exploration and exploitation

This problem can be framed as a sequential decision-making task, where quantum exploration algorithms or quantum reinforcement learning can achieve a quadratic speed-up.

Synthetic Data Generation

Clinical trials often struggle with insufficient data, especially when studying rare diseases or specific subpopulations. This lack of data makes it challenging to conduct statistically significant analyses, predict outcomes reliably, or create control arms.

Classical and quantum generative models can help reproduce realistic patient data that can aid in treatment outcome prediction and biomarker discovery.

Site Selection

In clinical trials, optimizing site selection—considering patient demographics, infrastructure, investigator expertise, and location—maximizes efficiency, patient recruitment, cost-effectiveness, and minimizes trial duration.

Site selection can be formulated as a complex constrained optimization problem that can be accelerated with quantum-enhanced methods, like QAOA and quantum annealing, to improve trial efficiency and resource allocation.

Cohort Identification Data Generation

Identifying the correct cohort of patients for a clinical trial involves defining inclusion and exclusion criteria based on various patient attributes. This process is complex due to high-dimensional, heterogeneous patient data.

Cohort selection can be framed as a classification problem, which can be efficiently addressed using quantum machine learning methods like quantum neural networks or quantum support vector machines.